Granules India Limited (GRANULES.BO)
INR 444.65
(1.8%)
INR 444.65
(1.8%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 22.95 Billion INR | 10.91% |
| 2022 | 20.69 Billion INR | 7.47% |
| 2021 | 19.25 Billion INR | 25.04% |
| 2020 | 15.4 Billion INR | 11.23% |
| 2019 | 13.84 Billion INR | -4.73% |
| 2018 | 14.53 Billion INR | 5.85% |
| 2017 | 13.73 Billion INR | 40.81% |
| 2016 | 9.75 Billion INR | 8.18% |
| 2015 | 9.01 Billion INR | 2.27% |
| 2014 | 8.81 Billion INR | 38.57% |
| 2013 | 6.36 Billion INR | 55.98% |
| 2012 | 4.07 Billion INR | 25.0% |
| 2011 | 3.26 Billion INR | 51.67% |
| 2010 | 2.15 Billion INR | 2.62% |
| 2009 | 2.09 Billion INR | -8.81% |
| 2008 | 2.29 Billion INR | 15.85% |
| 2007 | 1.98 Billion INR | 21.87% |
| 2006 | 1.62 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -32.25 Billion INR | -240.52% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 22.95 Billion INR | 10.91% |
| 2023 Q4 | 22.95 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 22.97 Billion INR | 0.0% |
| 2022 FY | 20.69 Billion INR | 7.47% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 20.69 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 22.59 Billion INR | 0.0% |
| 2021 Q2 | 17.58 Billion INR | 0.0% |
| 2021 Q4 | 19.25 Billion INR | 0.0% |
| 2021 FY | 19.25 Billion INR | 25.04% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q4 | 15.4 Billion INR | 0.0% |
| 2020 FY | 15.4 Billion INR | 11.23% |
| 2020 Q2 | 15.79 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 13.84 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 14.7 Billion INR | 0.0% |
| 2019 FY | 13.84 Billion INR | -4.73% |
| 2018 Q4 | 14.53 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 15.35 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 14.53 Billion INR | 5.85% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 11.58 Billion INR | 0.0% |
| 2017 Q4 | 13.73 Billion INR | 0.0% |
| 2017 FY | 13.73 Billion INR | 40.81% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 9.75 Billion INR | 0.0% |
| 2016 FY | 9.75 Billion INR | 8.18% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 8.81 Billion INR | 0.0% |
| 2015 Q2 | 7.29 Billion INR | 0.0% |
| 2015 Q4 | 9.01 Billion INR | 0.0% |
| 2015 FY | 9.01 Billion INR | 2.27% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2014 Q2 | 7.04 Billion INR | 0.0% |
| 2014 FY | 8.81 Billion INR | 38.57% |
| 2014 Q4 | 8.81 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q2 | 5.3 Billion INR | 0.0% |
| 2013 FY | 6.36 Billion INR | 55.98% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q4 | 6.36 Billion INR | 0.0% |
| 2012 Q2 | 6.51 Billion INR | 0.0% |
| 2012 Q4 | 4.07 Billion INR | 0.0% |
| 2012 FY | 4.07 Billion INR | 25.0% |
| 2011 FY | 3.26 Billion INR | 51.67% |
| 2010 FY | 2.15 Billion INR | 2.62% |
| 2009 FY | 2.09 Billion INR | -8.81% |
| 2008 FY | 2.29 Billion INR | 15.85% |
| 2007 FY | 1.98 Billion INR | 21.87% |
| 2006 FY | 1.62 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | -41.051% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 84.919% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -343.058% |
| Indoco Remedies Limited | 10.34 Billion INR | -121.947% |
| Achyut Healthcare Limited | 2.01 Million INR | -1140207.004% |
| Ajanta Pharma Limited | 10.71 Billion INR | -114.321% |
| Alkem Laboratories Limited | 48.6 Billion INR | 52.774% |
| Alpa Laboratories Limited | 307.12 Million INR | -7374.027% |
| Brooks Laboratories Limited | 248.6 Million INR | -9133.422% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -526.979% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -371.568% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -988.478% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 78.541% |
| Eris Lifesciences Limited | 38.26 Billion INR | 40.017% |
| FDC Limited | 3.7 Billion INR | -518.849% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 64.746% |
| Gufic Biosciences Limited | 5.59 Billion INR | -309.914% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -902.611% |
| Ipca Laboratories Limited | 33.74 Billion INR | 31.973% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -7634.998% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -671.858% |
| Lasa Supergenerics Limited | 541.92 Million INR | -4135.712% |
| Laurus Labs Limited | 42.71 Billion INR | 46.261% |
| Lupin Limited | 96.23 Billion INR | 76.148% |
| Mankind Pharma Limited | 23.87 Billion INR | 3.855% |
| Medicamen Biotech Limited | 940.36 Million INR | -2341.002% |
| Medico Remedies Limited | 438.24 Million INR | -5137.808% |
| Megasoft Limited | 1.85 Billion INR | -1138.673% |
| NATCO Pharma Limited | 10.53 Billion INR | -117.949% |
| Piramal Pharma Limited | 74 Billion INR | 68.982% |
| RPG Life Sciences Limited | 1.38 Billion INR | -1563.12% |
| Sigachi Industries Limited | 2.53 Billion INR | -806.834% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 87.496% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -1028.407% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -1869.976% |
| Unichem Laboratories Limited | 8.06 Billion INR | -184.467% |
| Wanbury Limited | 3.15 Billion INR | -627.436% |
| Windlas Biotech Limited | 1.76 Billion INR | -1202.228% |
| ZIM Laboratories Limited | 2.08 Billion INR | -1003.172% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 68.027% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -489.647% |
| Divi's Laboratories Limited | 18.99 Billion INR | -20.876% |
| Hester Biosciences Limited | 3.59 Billion INR | -538.558% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -796.235% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -2828.512% |
| Bal Pharma Limited | 2.51 Billion INR | -814.052% |
| Strides Pharma Science Limited | 37.68 Billion INR | 39.082% |
| Venus Remedies Limited | 1.39 Billion INR | -1548.074% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -178.211% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -104.619% |
| Shilpa Medicare Limited | 12.93 Billion INR | -77.494% |
| Aarti Drugs Limited | 11.5 Billion INR | -99.534% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -262.691% |
| Suven Life Sciences Limited | 148.62 Million INR | -15344.91% |
| Ind-Swift Limited | 13.45 Billion INR | -70.627% |
| Valiant Laboratories Limited | 1.05 Billion INR | -2069.07% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -114.367% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | -62.293% |
| Themis Medicare Limited | 1.88 Billion INR | -1116.119% |
| Hikal Limited | 12.99 Billion INR | -76.641% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 72.024% |
| Sequent Scientific Limited | 8.27 Billion INR | -177.419% |
| Novartis India Limited | 1.8 Billion INR | -1174.464% |
| Wockhardt Limited | 39.87 Billion INR | 42.427% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 62.538% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -7848.22% |
| Neuland Laboratories Limited | 5.49 Billion INR | -317.462% |
| Morepen Laboratories Limited | 4.45 Billion INR | -414.697% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -3464.992% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -1061.476% |